Abstract: Objective To detect the effect of Liraglutide on endoplasmic reticulum stress (ERS) in type 2 diabetes mellitus(T2DM) and non-alcoholic fatty liver disease(NAFLD) patients and analyze its clinic efficacy. Methods A total of 144 patients were enrolled in this study. Who were divided into: control group(n=72) and observation group(n=72). The control group was given metformin(0.5 g/time, 2 times/d for 12 weeks). The observation group was given Liraglutide (0.6 mg/d for 1 weeks, 1.2 mg/d for 11 weeks ). CHOP, ATF6, and GRP78 mRNA expression was detected by realtime PCR. The clinical efficacy and adverse reactions rate was compared. Results After treatment, the expression of FBG, 2hPBG, HbA1c, HOMA-IR, TG, TC, and LDL-C was significantly lower in observation group than that in control group (P<0.05). The 2^-△△Ct values of CHOP, ATF6, and GRP78 was significantly lower in observation group than that in control group (P<0.05). The clinic effective rate in observation group was 81.9%(59/72), which was lower than that of 62.5%(45/72) in control group (P<0.05). The adverse reactions rate was 2.8%(2/72) in control group and 4.2%(3/72) in observation group. There was no significant difference between the two groups (P>0.05). Conclusion Liraglutide can inhibit ERS to decrease blood glucose and lipid in T2DM combined with NAFLD patients, with effectively clinical efficacy and safety.

Key words: Liraglutide, Type 2 diabetes mellitus(T2DM), Non-alcoholic fatty liver disease(NAFLD), Endoplasmic reticulum stress (ERS)